FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab.

Front Immunol · 2023 · PMC10413977 · PMID 37575254

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Stimulation with Urelumab significantly enhanced GM-CSF, IFN-γ and IL-13 production whereas TNF-α was increased, but the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.